House Bill 7828
117th Congress(2021-2022)
PRICED Act
Introduced
Introduced in House on May 18, 2022
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
7828
Congress
117
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Jan Schakowsky
grade
Illinois
Arkansas
California
Connecticut
Illinois
Illinois
Michigan
Ohio
Texas
Washington
Wisconsin
No House votes have been held for this bill.
Summary
Price Relief, Innovation, and Competition for Essential Drugs Act or the PRICED Act
This bill allows biosimilars to be marketed five years after the reference brand-name biological product is licensed. Currently, brand-name biological products are provided a 12-year marketing-exclusivity period.
This shortened marketing-exclusivity period applies only to biological products licensed by the Food and Drug Administration after enactment of this bill.
May 18, 2022
Sort by most recent
05/18/2022
Referred to the House Committee on Energy and Commerce.
05/18/2022
Introduced in House
Public Record
Record Updated
Dec 30, 2022 12:04:02 AM